Literature DB >> 236516

Drug therapy: Sulfasalazine.

P Goldman, M A Peppercorn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 236516     DOI: 10.1056/NEJM197507032930105

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  20 in total

1.  Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.

Authors:  V S Chungi; L W Dittert; L Shargel
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

2.  Sulphasalazine is a potent inhibitor of prostaglandin 15-hydroxydehydrogenase: possible basis for therapeutic action in ulcerative colitis.

Authors:  J R Hoult; P K Moore
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

3.  Inhibition of folate enzymes by sulfasalazine.

Authors:  J Selhub; G J Dhar; I H Rosenberg
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

4.  Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.

Authors:  G O Cowan; K M Das; M A Eastwood
Journal:  Br Med J       Date:  1977-10-22

Review 5.  Sulfasalazine. Adverse effects and desensitization.

Authors:  S L Taffet; K M Das
Journal:  Dig Dis Sci       Date:  1983-09       Impact factor: 3.199

6.  Use of topical rectal therapy to preserve the rectum in surgery of ulcerative colitis.

Authors:  L Gallone; L Olmi; V Marchetti
Journal:  World J Surg       Date:  1980-09       Impact factor: 3.352

7.  Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.

Authors:  K Lauritsen; J Hansen; P Bytzer; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

8.  Sulfasalazine-induced colitis complicating idiopathic ulcerative colitis.

Authors:  F A Ring; N B Hershfield; G A Machin; R B Scott
Journal:  Can Med Assoc J       Date:  1984-07-01       Impact factor: 8.262

9.  Chitosan as a pore former in coated beads for colon specific drug delivery of 5-ASA.

Authors:  Wycliffe S Omwancha; Rama Mallipeddi; Brenda L Valle; Steven H Neau
Journal:  Int J Pharm       Date:  2012-11-28       Impact factor: 5.875

10.  Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.

Authors:  Y Miyachi; A Yoshioka; S Imamura; Y Niwa
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.